Krahasoni metodat

	Studim Adaptiv i Fazës IV	Studimi i Fazës IV
Fusha	Epidemiologji	Epidemiologji
Familja	Process / pipeline	Process / pipeline
Viti i origjinës	1990s–2000s (regulatory formalization of adaptive Phase IV designs)	Formalised 1970s–1990s (ICH E3 guideline 1994)
Krijuesi	Adaptive design principles developed by multiple statisticians; Phase IV framework established by regulatory bodies (FDA, EMA) in the late 20th century	Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks)
Lloji	Adaptive post-marketing clinical study design	Post-marketing observational or interventional study
Burimi themelues	Chow, S. C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman and Hall/CRC. ISBN: 978-1584889625	International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat.
Emërtime të tjera	adaptive post-marketing surveillance study, adaptive pharmacovigilance study, adaptive Phase IV trial, adaptive post-approval study	post-marketing surveillance study, post-approval study, Phase 4 study, PMS study
Të lidhura	6	5
Përmbledhja	An Adaptive Phase IV study is a post-marketing surveillance study conducted after a drug or intervention has received regulatory approval, augmented with pre-specified adaptive design elements that allow pre-planned modifications to the study protocol in response to accumulating data. These modifications may include sample size re-estimation, endpoint adjustments, or population enrichment, all governed by statistical rules set before the study begins, preserving scientific integrity while increasing efficiency.	A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life.